Aniel Sanchez
Overview
Explore the profile of Aniel Sanchez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
520
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuras M, Betancourt L, Hong R, Szadai L, Rodriguez J, Horvatovich P, et al.
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075679
Background: Melanoma is a highly heterogeneous disease, and a deeper molecular classification is essential for improving patient stratification and treatment approaches. Here, we describe the histopathology-driven proteogenomic landscape of 142...
2.
Skinner K, Fisher T, Lee A, Su T, Forte E, Sanchez A, et al.
bioRxiv
. 2025 Feb;
PMID: 39975277
The vast complexity of the proteome currently overwhelms any single analytical technology in capturing the full spectrum of proteoform diversity. In this study, we evaluated the complementarity of two cutting-edge...
3.
Guedes J, Pla I, Sanchez A, Marko-Varga G, Domont G, Sahlin K, et al.
Endocr Connect
. 2025 Jan;
14(2).
PMID: 39745472
Background: Prostate cancer therapy with surgical or chemical castration with gonadotropin-releasing hormone (GnRH) agonists has been linked to elevated follicle-stimulating hormone (FSH) levels, which may contribute to secondary health disorders,...
4.
Pla I, Szabolcs B, Peter P, Ujfaludi Z, Kim Y, Horvatovich P, et al.
Int J Dermatol
. 2024 Dec;
PMID: 39722169
Background: The utilization of PD1 and CTLA4 inhibitors has revolutionized the treatment of malignant melanoma (MM). However, resistance to targeted and immune-checkpoint-based therapies still poses a significant problem. Objective: Here,...
5.
Forte E, Sanders J, Pla I, Kanchustambham V, Hollas M, Huang C, et al.
Mol Cell Proteomics
. 2024 Nov;
23(12):100876.
PMID: 39521382
Cirrhosis, advanced liver disease, affects 2 to 5 million Americans. While most patients have compensated cirrhosis and may be fairly asymptomatic, many decompensate and experience life-threatening complications such as gastrointestinal...
6.
Huang C, Hollas M, Sanchez A, Bhattacharya M, Ho G, Sundaresan A, et al.
J Proteome Res
. 2024 Sep;
23(10):4694-4703.
PMID: 39312774
The dynamic range challenge for the detection of proteins and their proteoforms in human plasma has been well documented. Here, we use the nanoparticle protein corona approach to enrich low-abundance...
7.
Huang C, Hollas M, Sanchez A, Bhattacharya M, Ho G, Sundaresan A, et al.
bioRxiv
. 2024 Jul;
PMID: 39071411
The dynamic range challenge for detection of proteins and their proteoforms in human plasma has been well documented. Here, we use the nanoparticle protein corona approach to enrich low-abundant proteins...
8.
de Almeida N, Janosi A, Hong R, Rajeh A, Nogueira F, Szadai L, et al.
Clin Transl Med
. 2024 Jul;
14(7):e1773.
PMID: 39032005
No abstract available.
9.
Szadai L, Bartha A, Pla Parada I, Lakatos A, Pal D, Lengyel A, et al.
Front Oncol
. 2024 Jul;
14:1428182.
PMID: 39015503
Introduction: While Immune checkpoint inhibition (ICI) therapy shows significant efficacy in metastatic melanoma, only about 50% respond, lacking reliable predictive methods. We introduce a panel of six proteins aimed at...
10.
Forte E, Sanders J, Pla I, Kanchustambham V, Hollas M, Huang C, et al.
bioRxiv
. 2024 Jul;
PMID: 38948836
Cirrhosis, advanced liver disease, affects 2-5 million Americans. While most patients have compensated cirrhosis and may be fairly asymptomatic, many decompensate and experience life-threatening complications such as gastrointestinal bleeding, confusion...